Officials proposed limiting the amount of nicotine to make cigarettes less addictive, but it's unclear if the incoming administration will offer support.

Zyn and the retailers who sell the product have run afoul of regulators in recent years. The FDA in April of last year warned 119 retailers to stop selling Zyn to underage people, and the company was ordered to pay $1.2 million last year for violating Washington, D.C.’s smokeless tobacco ban.

Federal health officials on Thursday backed the public health benefits of nicotine pouches, authorizing Philip Morris International’s Zyn to help adult smokers cut back or quit cigarettes.

Altria Group stock outperformed the S&P 500 over the past year (total return), something you don't hear about so often. See why I upgrade my rating on MO to buy.

Shares of Altria Group, Inc. (NYSE:MO – Get Free Report) have received an average recommendation of “Hold” from the eight research firms that are covering the stock, Marketbeat.com reports. Two equities research analysts have rated the stock with a sell recommendation,

Altria just rewarded its shareholders again with a dividend. This high-yield stock has boosted its payout annually for more than 50 years.

The Food and Drug Administration authorized the marketing of 20 Zyn nicotine pouch products through the premarket tobacco product application

Even if the effort goes ahead under Trump, tobacco companies like Reynolds American and Altria are almost certain ... and said Wednesday that reducing nicotine would help nearly 13 million current ...

“The data show that these nicotine pouch products meet that bar ... similar products from other tobacco competitors, including Altria’s On pouches.

Philip Morris Intl. expands into cannabis via Avicanna partnership, focusing on medical research and innovation: How this move aligns with its long-term strategy.

Here are four Dividend Kings stocks that Baby Boomers can count on to deliver big and dependable payouts every quarter.